Filing Details

Accession Number:
0001209191-23-017553
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-09 16:47:39
Reporting Period:
2023-03-07
Accepted Time:
2023-03-09 16:47:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1591100 Andrea Loewen 5320 Legacy Drive
Plano TX 75024
Svp, Global Regulatory Affairs No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2023-03-07 15,000 $27.32 57,793 No 4 M Direct
Class A Common Stock Disposition 2023-03-07 17,836 $83.36 39,957 No 4 S Direct
Class A Common Stock Disposition 2023-03-07 1,200 $84.44 38,757 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Employee Stock Option (right to buy) Disposition 2023-03-07 15,000 $0.00 15,000 $27.32
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,000 2032-01-03 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $83.00 to $83.90. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $84.00 to $84.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The options began vesting in sixteen equal installments beginning on April 3, 2022. On February 28, 2023, based on the satisfaction of certain performance criteria, the options scheduled to vest on April 3, 2025, July 3, 2025, October 3, 2025, and January 3, 2026 vested immediately. The remainder of the vesting schedule will continue as originally stated, subject to continued service through each vesting date.